Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All coverage

DEA Proposes Specific Schedule I Listing for 3‑Chloromethcathinone (3‑CMC)

1 source analyzed5 claims checked0 primary sourcesUpdated 10d ago
5 unverifiable

What happened

Fact

The U.S. Drug Enforcement Administration announced a proposal to create a distinct Controlled Substances Code Number for 1‑(3‑chlorophenyl)‑2‑(methylamino)propan‑1‑one, commonly known as 3‑chloromethcathinone (3‑CMC), and to place it in Schedule I of the Controlled Substances Act. The agency notes that, while 3‑CMC is currently treated as a Schedule I substance under broader analog provisions, it does not yet have its own unique listing. The proposal indicates an intent to formalize the substance’s status, but the final regulatory action and effective date remain pending.

Layer 1 · Fact check

AI analysis

Each claim below was extracted from the reporting and checked against independently retrieved evidence. Expand a claim to see the evidence trail and reasoning.

Layer 2 · Biblical perspective

Biblical interpretation

Produced only after the factual analysis was complete. It examines the specific reported conduct — never a party, nation, or person as a whole — and never alters the factual findings above.

INSUFFICIENT CONTEXTFull biblical analysis

Moral topic

Regulation and listing of a controlled substance (3‑Chloromethcathinone) by governmental authority

Biblical principle

The passages do not directly address the moral status of governmental drug scheduling; they speak about authority and accountability but do not provide clear guidance on this specific modern issue.

Old Testament

“That the children of Israel might have for the time to come wherewith they should be admonished, that no stranger or any one that is not of seed of Aaron should come near to offer incense to the Lord, lest he should suffer as Core suffered, and all his congregation, according as the Lord spoke to Moses.”
Numbers 16:40 (DRV)

Illustrates the principle of proper authority and designated roles, but does not address drug regulation.

New Testament

“For the king knoweth of these things, to whom also I speak with confidence. For I am persuaded that none of these things are hidden from him. For neither was any of these things done in a corner.”
Acts 26:26 (DRV)

Shows that actions are visible to governing authority, yet offers no moral guidance on scheduling substances.

Explanation

The candidate verses Numbers 16:40 and Acts 26:26 discuss the role of authority and the expectation that leaders act justly, yet they do not speak to the moral evaluation of drug control policies. Therefore the biblical record offers insufficient context to classify the conduct as righteous or unrighteous.

Why these passages apply

Numbers 16:40 emphasizes that only those of Aaron’s lineage may approach the altar, highlighting the importance of proper authority in religious matters. Acts 26:26 notes that the king knows certain things, underscoring the visibility of actions before authority. Both verses illustrate principles of authority but do not directly address modern drug regulation.

Interpretive limitations

Only the supplied verses are used; no extrapolation beyond their explicit content is made. The verses do not speak to the ethics of drug scheduling, so a definitive moral judgment cannot be derived.

Source comparison

AI analysis

How each publication covered the same event — facts included, sourcing quality, framing, and omissions.

Facts included
  • The Drug Enforcement Administration (DEA) is establishing a specific listing and DEA Controlled Substances Code Number (drug code) for 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3‑chloromethcathinone; 3‑CMC) in schedule I of the Controlled Substances Act (CSA).
  • 3‑chloromethcathinone is not specifically listed in schedule I of the CSA with its own unique drug code.
  • The DEA is amending the schedule I hallucinogenic substances list in its regulations to separately include 3‑chloromethcathinone.
Sourcing
Low – the article relies solely on its own statement without external citations, official documents, or corroborating sources.
Framing
The piece presents itself as a factual report of a regulatory action without offering analysis or opinion; however, it makes an unsupported claim about the hallucinogenic status of 4‑chloromethcathinone.
Omissions
The article does not provide context about the legal process for adding a substance to Schedule I, the criteria used by the DEA, any public comment period, the potential impact on users or researchers, or health and safety information about 3‑CMC.
Rhetorical notes (3)
Framing · Technical Jargon · Causal Claim

Layer 3 · Reporting analysis

AI analysis

Framing

seen in 1 article

The opening frames the DEA action as a definitive regulatory step, implying authority and finality.

In Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance · Federal Register

Technical Jargon

seen in 1 article

Use of specialized terminology conveys officialdom but may be opaque to lay readers.

In Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance · Federal Register

Causal Claim

seen in 1 article

The article links the scheduling decision directly to chemical similarity without providing supporting evidence or regulatory criteria.

In Specific Listing for 3-Chloromethcathinone, A Currently Controlled Schedule I Substance · Federal Register

Uncertainty

Where evidence is thin or reporting diverges, the fact-check entries above say so explicitly rather than manufacturing certainty. Claims marked “Unverifiable” or “Missing context” reflect genuine gaps in the available evidence, not editorial judgment.

Evidence

Fact

Every source the pipeline retrieved, grouped by evidence tier. Repeated reporting of the same original claim is not counted as independent confirmation.

No evidence records published for this event yet.

Methodology

AI analysis

This analysis was produced by an automated daily pipeline: feeds are retrieved and normalized, URLs canonicalized, near-duplicates removed, and articles describing the same underlying event are clustered. Claims are extracted as atomic, testable propositions; evidence is retrieved in tiers from primary sources down to commentary; each claim is verified against that evidence; then reporting analysis and — separately — biblical analysis are performed. Every stage emits validated structured data, and any stage that fails validation is quarantined for human review instead of being published.

Publisher reputation, author reputation, and ideology never determine whether a factual claim is true. The biblical classifier examines only the specific reported conduct, and its result cannot change the factual findings.

AI disclosure

AI-generated analysis.
Evidence checked:
0
Primary sources:
0
Confidence:
Low
Last analyzed:
Nov 6, 2026, 4:44 AM CST
Pipeline:
2.1.0

Articles in this event